Abstracts tagged "Epidemiology"

Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1805 • ACR Convergence 2023
Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Sho Fukui¹, Masato Okada², Tomohiro Shinozaki³, Takahiro Asano², Takehiro Nakai², Hiromichi Tamaki², Mitsumasa Kishimoto⁴, Hiroshi Hasegawa⁵, Takeaki Matsuda⁵, Javier Marrugo¹, Sara Tedeschi¹ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Boston, MA, ²St. Luke's International Hospital, Tokyo, Japan, ³Tokyo University of Science, Tokyo, Japan, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Kyorin University, Tokyo, Japan, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Cross-sectional epidemiologic studies support a direct relationship between alcohol intake and serum urate (SU). These observations are parts of the basis for gout recommendations…
Abstract Number: 1957 • ACR Convergence 2023
Non-Linear Mendelian Randomization Analyses Support a Role for Low Vitamin D Status in Sarcopenia Risk
Tingting Sha¹, Yilun Wang², Yuqing Zhang³, Nancy Lane⁴, Changjun Li⁵, Jie Wei⁶, Chao Zeng² and Guanghua Lei², ¹Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴University of California, Hillsborough, CA, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Vitamin D deficiency is commonly associated with sarcopenia; however, the latest International Clinical Practice Guidelines for Sarcopenia do not recommend vitamin D supplementation for…
Abstract Number: 2277 • ACR Convergence 2023
Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences
Iñigo Rúa-Figueroa¹, Rosana M Quintana², JULIA MARTINEZ BARRIO³, Mercedes García⁴, Maria Galindo-Izquierdo⁵, Lucila Garcia⁶, Jaime Calvo- Alén⁷, Carla Gobbi⁸, Esther Uriarte Isacelaya⁹, Paula Alba⁸, Eva Tomero Muriel¹⁰, Verónica Bellomio¹¹, Mercedes Freire González¹², Susana Roverano⁶, Victor Martinez-Taboada¹³, Analia Patricia Alvarez¹⁴, Eva Salgado-Pérez¹⁵, Cesar Enrique Graf¹⁶, Paloma Vela¹⁷, Cecilia Pisoni¹⁴, Antonio Fernandez-Nebro¹⁸, Valeria Arturi¹⁹, Clara Sanguesa Gomez²⁰, Catalina Gomez¹⁴, Javier Narvaez²¹, Zulema Plaza²², Gregorio Santos Soler²³, Silvia Papasidero²⁴, José Ángel Hernández Beriain²⁵, Raul Paniego⁶, Angela Pecondón²⁶, Maria Celina De La Vega⁶, Oihane Ibarguengoitia-Barrena²⁷, Emma Civit⁸, Gema Bonilla²⁸, Luciana Gonzalez Lucero¹⁴, Vicente Torrente-Segarra²⁹, Maria Victoria Martire⁶, Ana Paula Cacheda³⁰, Rodrigo Aguila Maldonado¹⁴, Maria J. García-Villanueva³¹, Sergio Gordon¹⁴, Clara Moriano Morales³², Marina Micelli⁶, Loreto Horcada³³, Romina Nieto³⁴, Nuria Lozano Rivas³⁵, Gretel Rausch¹⁴, Guillermo Pons-Estel³⁴ and Jose-Maria Pego-Reigosa³⁶, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁵Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁶RELESSAR, CABA, Argentina, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸RELESSAR, Cordoba, Argentina, ⁹Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ¹¹RELESSAR, Tucuman, Argentina, ¹²Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹³Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁴Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ¹⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ¹⁶RELESSAR, ENTRE RIOS, Argentina, ¹⁷Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹⁸Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁹RELESSAR, La Plata, Argentina, ²⁰Severo Ochoa Hospital, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Universidad Autónoma de Madrid, Madrid, Spain, ²³Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ²⁴Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Universitario Miguel Servet, Zaragoza, Madrid, Spain, ²⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁹Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ³⁰Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ³¹Hospital Ramón y Cajal, Madrid, Spain, ³²Rheumatology, Hospital Universitario de León, León, Spain, ³³Hospital de Navarra, Pamplona, Spain, ³⁴RELESSAR, Rosario, Argentina, ³⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ involvement, associated with substantial morbidity and mortality. A characteristic that distinguishes lupus patients…
Abstract Number: 2516 • ACR Convergence 2023
The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Katrina Nguyen¹, Jennifer Du¹, Jiaxiao shi² and Antony Lin¹, ¹Kaiser SCAL, Fontana, CA, ²SCPMG, Pasadena, CA
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
Abstract Number: 0138 • ACR Convergence 2023
Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review
Jiyoon Choi¹, Kimberly Hofer², Nishu Gaind², Mir Sohail Fazeli², Robert Carroll³, Antoine G Sreih³ and Antonia Christodoulou³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Evidinno Outcomes Research Inc., Vancouver, BC, Canada, ³Bristol Myers Squibb, Princeton Pike, NJ
Background/Purpose: Sjögren's syndrome (SjS) is a chronic autoimmune disease that has been historically categorized into primary (manifesting alone; pSjS) or secondary (appearing alongside another underlying…
Abstract Number: 0467 • ACR Convergence 2023
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Rashmi Dhital, Rebecca Baer and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) and antiphospholipid syndrome (APS) are autoimmune conditions with increased risks of cardiovascular complications as well as negative pregnancy consequences. We…
Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 0985 • ACR Convergence 2023
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Daniel Solomon¹, Fredrik Johansson², Hongshu Guan³, Leah Santacroce⁴, Lin Guo⁵, Wendi Malley⁵ and Heather Litman⁵, ¹Brigham and Women's Hospital, Newton, MA, ²Chalmers University of Technology, Goteborg, Sweden, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵CorEvitas, LLC, Waltham, MA
Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
Abstract Number: 1806 • ACR Convergence 2023
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Daming Shao¹, Jiyoung Seo¹, Shaunak Mangeshkar¹, Natalia Nazarenko¹, Stepan Esagian¹, Leonidas Palaiodimos¹ and Damianos Kokkinidis², ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
Abstract Number: 1979 • ACR Convergence 2023
Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis
Jie Wei¹, david Hunter², Nancy Lane³, Jing Wu⁴, Chao Zeng⁵, Guanghua Lei⁵ and Yuqing Zhang⁶, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³University of California, Hillsborough, CA, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: The current international guidelines recommend weight loss for pain relief and functional improvement in overweight or obese patients with knee or hip osteoarthritis; however,…
Abstract Number: 2281 • ACR Convergence 2023
Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
Ke-Hung Lin¹, Tzu-Min Lin¹ and Chi-Ching Chang², ¹Taipei Medical University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disorder with high morbidity and mortality. Although CNS infections account for only 0.53–2.25% of all infections…
Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Andriko Palmowski¹, Gabriela Schmajuk², Jinoos Yazdany³, Patti Katz⁴, Jing Li⁵, Rachael Stovall⁵, Emma Kersey⁵, Sabrina Mai Nielsen⁶, Robin Christensen⁷, Henning Bliddal⁸, Zhivana Boyadzhieva⁹, Udo Schneider⁹, Tobias Alexander¹⁰, Burkhard Muche¹¹, Sandra Hermann¹¹, Edgar Wiebe¹¹ and Frank Buttgereit¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of California San Francisco, San Rafael, CA, ⁵University of California San Francisco, San Francisco, CA, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Charité Universitatsmedizine - Berlin, Berlin, Germany, ¹⁰Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ¹¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.